Radioimmunotherapy strategies for non-Hodgkin's lymphomas

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Corcoran, M C ^b   Eary, J ^b   Bernstein, I ^b   Press, O W ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

bone marrow transplantation; immunotherapy; monoclonal antibodies; non Hodgkin's lymphoma; radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY Y 90;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG RESEARCH; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0031009759     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S133     Document Type: Conference Paper

References (49)

1. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-7.
2. Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-91.
3. Bearman S, Appelbaum F, Buckner CD. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-8.
4. Vuist WMJ, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotype antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 1994; 83: 899-906.
5. Waldmann TA, Goldman CK, Bongiovanni KF et al. Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805-16.
6. Waldmann TA, Pastan IH, Gansow OA et al. The multichain interleukin-2 receptor: A target for immunotherapy. Ann Intern Med 1992; 116: 148-60.
7. Taylor C, Linden H, Rubin M et al. Phase Ia trial of mouse IgA anti-transferrin receptor monoclonal antibody 42/6 in patients with cancer. Proc Am Assoc Cancer Res 1994; 35: 218.
8. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497-515.
9. Press OW, Appelbaum FR, Ledbetter JA et al. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B lymphomas. Blood 1987; 69: 584-91.
10. Dyer MJS, Hale G, Hayoe FG et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989; 73: 1431-9.
11. Hale G, Clark MR, Marcus R et al. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-9.
12. Brown SL, Miller RA, Horning SJ et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651-61.
13. Brown SL, Miller RA, Levy R. Anti-idiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16: 199-210.
14. Meeker TC, Lowder J, Maloney DG et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349-63.
15. Miller RA, Hart S, Samoszuk M et al. Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med 1989; 321: 851-7.
16. Maloney DG, Brown S, Czerwinski DK et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992; 80: 1502-10.
17. LoBuglio AF, Wheeler RH, Trang J et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Immunology 1989; 86: 4220-4.
18. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
19. Maloney DG, Grillo-Lopez AJ, Bodkin D et al. IDEC-C2B8 anti-CD20 antibody: Results of long-term follow-up of relapsed NHL phase II trial patients. Blood 1995; 86 (Suppl): 54a.
20. Czuczman MS, Grillo-Lopez AJ, Jonas C et al. IDEC-C2B8 and CHOP chemoimmunotherapy of low-grade lymphoma. Blood 1995; 86 (Suppl): 55a.
21. Simpkin DJ, Mackie TR. EGS4 Monte Carlo determination of beta dose kernel in water. Med Physiol 1990; 17: 179-86.
22. Langmuir VK, Sutherland RM. Radiobiology of radioimmunotherapy: Current status. Antibody Immunoconj Radiopharmaceut 1988; 1: 195-211.
23. Wheldon TE. O'Donoghue JA. The radiobiology of targeted radiotherapy. Int J Radial Biol 1990; 58: 1-21.
24. Dillehay LE, Williams JR. Radiobiological characteristics of radiolabeled immunoglobulin therapy (RIT). In DeNardo GL (ed): Biology of Radionuclide Therapy. Washington, DC: American College of Nuclear Physicians 1989; 262.
25. Foon KA, Schroff RW, Gale RP. Surface markers on leukemia and lymphoma cells: Recent advances. Blood 1982; 60: 1-19.
26. Horibe K, Nadler LM. Human B cell associated antigens denned by monoclonal antibodies. In Heise ER (ed): Lymphocyte Surface Antigens. New York: ASHI 1984; 309-23.
27. Travis EL, Peters LJ, McNeill J et al. Effect of dose-rate on total body irradiation: Lethality and pathologic findings. Radiother Oncol 1985; 4: 341-51.
28. Shawler DL, Bartholomew RM, Smith LM et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530-5.
29. Schroff RW, Foon KA, Beatty SM et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879-85.
30. Zimmer AM, Rosen ST, Spies SM et al. Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: Analysis of retreatment following plasmapheresis. J Nucl Med 1988; 29: 174-80.
31. Zimmer AM, Kazikiewicz JM, Spies WG et al. Analysis of human antimurine mediated immunoglobulin complex formation in patients receiving murine monoclonal antibodies. Antibody Immunoconj Radiopharmaceut 1989; 2: 71-82.
32. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled antibody therapy of B-cell lymphomas with autologous bone marrow support. N Engl J Med 1993; 329: 1219-24.
33. Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with I-131-anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
34. Czuezman MS, Straus DJ, Divgi CR et al. Phase I dose-escalation trial of I-131 labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2021-9.
35. Scheinberg DA, Straus DJ, Yeh SD et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression. J Clin Oncol 1990; 8: 792-803.
36. Goldenberg DM, Horowitz JA, Sharkey RM et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with I-131 labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548-64.
37. Press OW, Eary JF, Badger CC et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-I (anti-CD37) antibody. J Clin Oncol 1989; 7: 1027-38.
38. Kaminski MS, Fig L, Zasadny K et al. Imaging, dosimetry, and radioimmunotherapy of I-131 labeled anti-CD37 antibody in B cell lymphoma. J Clin Oncol 1992; 10: 1696-1711.
39. Parker BA, Vassos AB, Halpern SE et al. Radioimmunotherapy of human B-cell lymphoma with yttrium-90 conjugated anti-idiotype monoclonal antibody. Cancer Res 1990; 50 (Suppl); 1022-8s.
40. DeNardo SJ, DeNardo GL, O'Grady LF et al. Treatment of B-cell malignancies with I-131 lym-1 monoclonal antibodies. J Cancer 1988; 3 (Suppl): 96-101.
41. DeNardo GL, DeNardo SJ, O'Grady LF et al. Fractionated radioimmunotherapy of B-cell malignancies with I-131 lym-1. Cancer Res 1990; 50 (Suppl): 1014-16s.
42. DeNardo SJ, DeNardo GL, O'Grady LF et al. Pilot studies of radioimmunotherapy of B-cell lymphoma and leukemia using I-131 lym-1 antibody. Antibody Immunoconj Radiopharmaceut 1988; 1: 17-33.
43. Saletan SL, Norvitch ME, Rosen ST et al. A phase I/II escalating-dose safety, dosimetry, and efficacy study of radiolabeled monoclonal antibody lym-1. Pearl River, NY: American Cyanamid Company, Medical Research Division, Clinical Research-Oncology 1965.
44. Raubitschek AA. Yttrium-90-labeled T101 in the treatment of hematologic malignancies. Proc Int Conf Monoclonal Antibody Conjugates for Cancer. 15-17 March 1990, San Diego, CA.
45. Rosen ST, Zimmer AM, Goldman-Leikin R et al. Progress in the treatment of cutaneous T-cell lymphomas with radiolabeled monoclonal antibodies. Int J Radiat Appl Instr Nucl Med Biol part B. 1989; 16: 667-8.
46. Zimmer AM, Kaplan EH, Kazikiewicz J et al. Pharmacokinetics of I-131 T101 monoclonal antibody in patients with chronic lymphocytic leukemia. Antibody Immunoconj Radiopharmaceut 1988; 1: 291-303.
47. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled antibody therapy of lymphomas. In DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer Updates V. Philadelphia: J. B. Lippincott 1994; 1-13.
48. Kaminski MS, Fenner MC, Estes J et al. Phase I/II trial results of I-131-anti B1 (anti-CD20) non-myeloablative radioimmunotherapy (RIT) for refractory B-cell lymphoma. Proc Am Soc Clin Oncol 1996; 15: 414.
49. Press OW, Eary JF, Appelbaum FR et al. Phase II trial of iodine-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-340.